TXNRD1 and neoplasm: Both auranofin and the more specific TXNRD1 inhibitor, TRi-1, suppress tumor development in PyMT-MMTV mice that spontaneously develop malignant breast tumors [12], as well as in other triple negative breast cancer models, particularly if combined with anti-PD-L1 antibody [12,16].